Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 3, 1999, Pages 603-608

  Kumar, Princy N ^a   Sweet, Donna E ^b   McDowell, James A ^c   Symonds, William ^c   Lou, Yu ^c   Hetherington, Seth ^c   LaFon, Stephen ^c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG SAFETY; DYSPEPSIA; FEMALE; HEADACHE AND FACIAL PAIN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033045943     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.3.603     Document Type: Article

References (12)

1. Child, S., J. Montaner, C. Tsoukas, M. Fanning, T. Le, R. A. Wall, and J. Ruedy. 1991. Canadian multicenter azidothymidne trial: AZT pharmacokinetics. J. Acquired Immune Defic. Syndr. 4:865-870.
2. Ching, S. V., K. M. Ayers, R. E. Dornsife, G. L. Grebe, and J. L. Howard. 1994. Nonclinical toxicology and in vitro toxicity studies with the novel anti-HIV agent (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) succinate, abstr. 188, p. 92. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Daluge, S. M., S. S. Good, M. B. Faletto, W. H. Miller, M. H. St. Clair, L. R. Boone, M. Tisdale, N. R. Parry, J. E. Reardon, R. E. Dornsife, D. R. Averett, and T. A. Krenitsky. 1997. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob. Agents Chemother. 41:1082-1093.
4. Dudley, M. N., K. K. Graham, S. Kaul, S. Geletko, L. Dunkle, M. Browne, and K. Mayer. 1992. Pharmacokinetics of stavudine in patients with AIDS or AIDS-retated complex. J. Infect. Dis. 166:480-485.
5. Faletto, M. B., W. H. Miller, E. P. Garvey, M. H. St. Clair, S. M. Daluge, and S. S. Good. 1997. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob. Agents Chemother. 41: 1099-1107.
6. Good, S. S., B. X. Owens, M. B. Faletto, W. B. Mahony, and B. A. Domin. 1994. Disposition in monkeys and mice of (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) succinate. a potent inhibitor of HIV, abstr. 186, p. 92. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Good, S. S., S. M. Daluge, S. V. Ching, M. M. Ayers, W. B. Mahony, M. B. Falletto, B. A. Domin, B. S. Owens, R. E. Dornsife, J. A. McDowell, S. W. LaFon, and W. T. Symonds. 1995. 1592U89 succinate-preclinical toxicological and disposition studies and preliminary clinical pharmacokinetics. Antivir. Res. 26:A229.
8. Klecker, R. W., Jr., J. M. Collins, R. C. Yarchoan, R. Thomas, N. McAtee, S. Broder, and C. E. Myers. 1988. Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. J. Clin. Pharmacol. 28:837-842.
9. Knupp, C. A., W. C. Shyu, R. Dolin, F. T. Valentine, C. McLaren, R. R. Martin, K. A. Pittman, and R. H. Barbhaiya. 1991. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin. Pharmacol. Ther. 49:523-535.
10. McDowell, J. A., W. T. Symonds, P. N. Kumar, D. E. Sweet, M. R. Blum, and S. W. LaFon. 1995. Initial phase-I study of anti-HIV agent 1592U89 in a single-dose escalation design including food effect and dosage form evaluation, abstr. I109, p. 224. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
11. St. Clair, M. H., J. Millard, J. Rooney, M. Tisdale, N. Parry, B. M. Sadler, M. R. Blum, and G. Painter. 1996. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antivir. Res. 29: 53-56.
12. Yuen, G. J., D. M. Morris, P. K. Mydlow, S. Haidar, S. T. Hall, and E. K. Hussey. 1995. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J. Clin. Pharmacol. 35:1174-1180.